ALIVE Israel HealthTech Fund
VC Fund
Tel Aviv, Israel
ALIVE Israel HealthTech Fund is a pioneer mid-to-late stage HealthTech fund leveraging an exclusive ecosystem.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 69%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries ALIVE Israel HealthTech Fund invests in
Stages ALIVE Israel HealthTech Fund invests in
Countries ALIVE Israel HealthTech Fund invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $4.4M–$17M
- Series B
- $22M–$30M
- Series C
- $30M–$55M
Investment Focus
Industry
- Health Care 12 (75%)
- Biotechnology 6 (38%)
- Medical Device 6 (38%)
- Medical 5 (31%)
- mHealth 3 (19%)
Stage
- Series A 4 (25%)
- Series B 3 (19%)
- Series C 3 (19%)
- Venture - Series Unknown 3 (19%)
- Seed 1 (6%)
Country
- Israel 10 (63%)
- United States 3 (19%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Ari Shamiss
Co-Founder and Managing General Partner
|
Co-Founder and Managing General Partner | Total investments: 3 | Find email | |
Dudi Klein
Co-Founder and Managing Partner
|
Co-Founder and Managing Partner | Total investments: 1 | Find email | |
Dudi Klein
Co-Founder and Managing Partner
|
Co-Founder and Managing Partner | Total investments: 3 | Find email | |
Michel Habib
Co-Founder & Managing General Partner
|
Co-Founder & Managing General Partner | Total investments: 4 | Find email | |
Prof. Rafael Beyar
Co-Founder and Managing General Partner
|
Co-Founder and Managing General Partner | Total investments: 4 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| UltraSight aims to revolutionize ultrasound through the power of machine learning to enable more accurate and timely clinical decisions. The UltraSight automated guidance system helps bring the benefits of cardiac imaging to healthcare professionals in new care settings, allowing patients access to ultrasound anywhere. UltraSight won the TCT 2020Innovation Competition which took place during the Transcatheter Cardiovascular Therapeutics world conference. For mor information please visit us at www.ultrasight.com | $24M / Series B / Sep 23, 2026 | ||
| Navina develops an AI-driven platform that restructures patient data into intuitive patient portraits for better diagnoses and care.Born from the vision of replacing the time-consuming chaos of patient data with a logical, actionable platform, Navina enables physicians to assess even the most complex cases in minutes. Its technology restructuresdisorganized data into an intelligible patient portrait, intuitively organized to support sophisticated and empathetic patient care. By leveraging AI and machine learning, the platform ensures that the most important information is immediately clear, diagnostically linked, and contextually surfaced, providing physicians with a comprehensive view of each patient’s data.The result is improved patient wellness and enhanced financial performance for both providers and payers. Navina is also a partner of the American Academy of Family Physicians (AAFP) Innovation Lab. | $55M / Series C / Mar 25, 2025 | ||
| Founded in October, 2012, Magenta Medical Ltd. is a privately held company that is engaged in the development of novel device solutions for the treatment of acute and chronic heart failure. | $105M / Venture - Series Unknown / Jul 23, 2024 | ||
| Vessi Medical, an Israeli medical device startup, brings a new approach to treat Non-Muscle-Invasive Bladder Cancer (NMIBC). Vessi uses surface cryotherapy, a treatment that utilizes extreme cold, to freeze and destroy abnormal tissue.Categorized as surface cancer on the inside lining of the bladder, NMIBC affects 2 million people globally with300,000 new cases reported every year. TransUrethral Resection of Bladder Tumor (TURBT) is the leading first-line therapy. Yet, this invasive surgical procedure, requiring a costly hospital stay performed under general anesthesia, can often be inadequate. In up to 80% of cases the cancer returns, with increased complications as patients need multiple repeat procedures that further reduce quality of life.Vessi's minimally invasive NMIBC solution provides a new, first-line, office-based therapy alternative to surgery. The company's patent-pending, bladder-specific cryotherapy technology eliminates costly and problematic repeat surgeries seen with TURBT, reducing the need for hospital stay by providing in office or ambulatory treatment. The technology successfully ablates unwanted tissue, reduces the risk of dispersed cancers cells, all while causing no bladder damage. The Vessi system consists of a standalone console and a disposable catheter that is inserted into the bladder. Vessi is backed by the Trendlines Group, a leading Israeli early stage investor, and led by seasoned medical device and cryotherapy veterans. The company has already demonstrated promising proof of concept in animals with its Alpha product. Vessi’s first application will initially target the $1.2 billion NMIBC market, with future applications for the treatment of overactive bladder and urinary tract infections, both billion-dollar markets. | $16.5M / Series A / Feb 14, 2024 | ||
| Gina Life is femtech company developing a platform of biomarkers strategy supported by AI for early detection in women’s health space. | $3.1M / Seed / Aug 29, 2023 | ||
| Append Medical develops a next-generation transcatheter Left Atrial Appendage (LAA) closure system.The Append Medical solution is in the pre-clinical in-vivo trial phase. It is intended to become a differentiated solution in the LAA closure market, which has been estimated to reach $25B within several years. This is the second-fastest growingsegment of the medical device market, with potential sales of $500M in 2019. Append Medical is a member of MEDX Xelerator, a medtech incubator backed by Boston Scientific, Intellectual Ventures, MEDX Ventures and Sheba Medical Center. | $4.4M / Series A / Jul 06, 2023 | ||
| Founded in October, 2012, Magenta Medical Ltd. is a privately held company that is engaged in the development of novel device solutions for the treatment of acute and chronic heart failure. | $55M / Venture - Series Unknown / May 03, 2023 | ||
| Thesis offers personalized brain supplements that cater to all types of brains. They create potent nutritional compounds to improve mental function and provide individualized suggestions depending on their customers' goals and brain chemistry. | $8.4M / Series A / May 02, 2023 | ||
| Wisdo is an AI-powered Social Health platform harnessing the power of data and meaningful connections to improve health. | $5M / Series A / Jan 05, 2023 | ||
| Navina develops an AI-driven platform that restructures patient data into intuitive patient portraits for better diagnoses and care.Born from the vision of replacing the time-consuming chaos of patient data with a logical, actionable platform, Navina enables physicians to assess even the most complex cases in minutes. Its technology restructuresdisorganized data into an intelligible patient portrait, intuitively organized to support sophisticated and empathetic patient care. By leveraging AI and machine learning, the platform ensures that the most important information is immediately clear, diagnostically linked, and contextually surfaced, providing physicians with a comprehensive view of each patient’s data.The result is improved patient wellness and enhanced financial performance for both providers and payers. Navina is also a partner of the American Academy of Family Physicians (AAFP) Innovation Lab. | $22M / Series B / Oct 27, 2022 | ||
| See all 16 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does ALIVE Israel HealthTech Fund invest in?
ALIVE Israel HealthTech Fund invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series A and Series B stage. Most of the 16 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is ALIVE Israel HealthTech Fund's check size?
ALIVE Israel HealthTech Fund typically joins rounds of $4.4M–$17M at Series A, $22M–$30M at Series B and $30M–$55M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds ALIVE Israel HealthTech Fund participates in.
How do I contact ALIVE Israel HealthTech Fund?
Public channels for ALIVE Israel HealthTech Fund include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at ALIVE Israel HealthTech Fund?
The team at ALIVE Israel HealthTech Fund includes Ari Shamiss (Co-Founder and Managing General Partner), Dudi Klein (Co-Founder and Managing Partner) and Dudi Klein (Co-Founder and Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
